Bd reports fourth quarter and full year fiscal 2024 financial results

Strong growth and margin execution drives performance in quarter q4 revenue of $5.4 billion increased 6.9% as reported, 7.4% currency-neutral and 6.2% organic q4 gaap and adjusted diluted eps from continuing operations of $1.45 and $3.81 grew 173.6% and 11.4%, respectively fy24 revenue of $20.2 billion increased 4.2% as reported and currency neutral, 4.6% adjusted currency-neutral, and 5.0% organic fy24 gaap and adjusted diluted eps from continuing operations of $5.93 and $13.14 grew 16.3% and 7.6%, respectively fy24 cash from continuing operations grew 28.5% to $3.8 billion and free cash flow grew 47.4% to $3.1 billion, increasing $0.9 billion and $1.0 billion since the prior year, respectively company issues fy25 revenue guidance including gaap growth of 8.9% to 9.4%, adjusted currency-neutral growth of 8.8% to 9.3% and organic growth of 4.0% to 4.5% company issues fy25 adjusted diluted eps guidance of $14.25 to $14.60 1, which reflects growth of about 10% at the midpoint franklin lakes, n.j. , nov. 7, 2024 /prnewswire/ -- bd (becton, dickinson and company) (nyse: bdx), a leading global medical technology company, today announced results for its fiscal 2024 fourth quarter and full year which ended september 30, 2024.
BDX Ratings Summary
BDX Quant Ranking